Skip to main content

What the FDA labels say about taking them together

Cannabidiol and rifampin

Cannabidiol's FDA label of May 29, 2026 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name cannabidiol. The cannabidiol label: “Drugs on EPIDIOLEX Strong CYP3A4 or CYP2C19 Inducers Concomitant use with a strong CYP3A4 and CYP2C19 inducer decreased cannabidiol and 7-hydroxy-cannabidiol (7-OH-CBD) plasma concentrations by approximately 32% and 63%.”

Check it at the source: the cannabidiol FDA label on DailyMed (effective May 29, 2026, Jazz Pharmaceuticals, Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).

What does the cannabidiol label say about rifampin?

Cannabidiol label, drug interactions

Drugs on EPIDIOLEX Strong CYP3A4 or CYP2C19 Inducers Concomitant use with a strong CYP3A4 and CYP2C19 inducer (rifampin 600 mg once daily) decreased cannabidiol and 7-hydroxy-cannabidiol (7-OH-CBD) plasma concentrations by approximately 32% and 63%.

Source: FDA drug label (Epidiolex), Jazz Pharmaceuticals, Inc., effective May 29, 2026 (SPL set 8bf27097-4870-43fb-94f0-f3d0871d1eec), via openFDA; the full label on DailyMed

What does the rifampin label say about cannabidiol?

Rifampin's label (effective February 11, 2026) does not name cannabidiol in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Cannabidiol generic labelers
13Rifampin generic labelers
CannabidiolRifampin
Labeled forn/an/a
Boxed warningNoNo
Pharmacy cost (NADAC)n/a$0.679 per capsule 300 mg capsule
Shortage nowNo current entryIn shortage

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?